Abbisko Cayman said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly.
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market as it has done in the United States.
The tech sector is experiencing a sharp global sell-off today, dragging down chipmakers like Intel, AMD, Micron, and even the artificial intelligence (AI) darling – Nvidia. What's driving this weakness is a combination of a global market contagion (KOSPI crashed over 10% prompting a trading halt), resurgent fears of the US rate hike, and a valuation reset on the AI trade.
Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of promise in clinical trials.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
These players sell market-leading products and are tackling growth industries. Holding for several years, rather than a short period, allows investors to fully benefit from each company's story.
Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate compares to competing programs that are still in clinical trials.
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry.
INDIANAPOLIS, June 22, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.